Tech Company Financing Transactions
Brixton Biosciences Funding Round
On 5/14/2024, Brixton Biosciences received $33 million in Series B investment from Schooner Capital, Catalyst Health Ventures and Excelestar Ventures.
Transaction Overview
Company Name
Announced On
5/14/2024
Transaction Type
Venture Equity
Amount
$33,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to initiate pivotal clinical studies in both chronic and acute pain indications.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
1000 Massachusetts Ave. 101
Cambridge, MA 02138
USA
Cambridge, MA 02138
USA
Phone
Website
Email Address
Overview
Neural Ice� therapy will put pain on ice with a simple injection that is intended to induce a reversible inhibition of the nerve and provide pain relief that lasts exponentially longer than the current methods.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sameer Sabir
Chief Medical Officer
Michael Fishman
Chief Medical Officer
Joanna Xylas
Chief Technical Officer
Charles Sidoti
VP - Bus. Development
David Curd
VP - Product Management
Aaron McPherson
VP - R & D
Tom Merrill
VP - Regulatory Affairs
Olivier Kagan
Browse more venture capital transactions:
Prev: 5/14/2024: ndustrial venture capital transaction
Next: 5/14/2024: Nfinite Nanotech venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs